Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome

Diabetes Care

Volumn 29, Issue 2, 2006, Pages 300-305

  Baillargeon, Jean Patrice ^a   Diamanti Kandarakis, Evanthia ^b   Ostlund Jr , Richard E ^c   Apridonidze, Teimuraz ^d   Iuorno, Maria J ^d   Nestler, John E ^d  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRO CHIRO INOSITOL; INOSITOL; INSULIN; UNCLASSIFIED DRUG; TESTOSTERONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CHEMICAL ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; FEMALE; GAS CHROMATOGRAPHY; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; KIDNEY CLEARANCE; KIDNEY CONCENTRATING CAPACITY; MASS SPECTROMETRY; MEDICAL ASSESSMENT; MULTIVARIATE ANALYSIS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; ADOLESCENT; ANALYSIS OF VARIANCE; BLOOD; BLOOD PRESSURE; GLUCOSE TOLERANCE TEST; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; STATISTICAL MODEL; URINE; WAIST HIP RATIO;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; BLOOD PRESSURE; BODY MASS INDEX; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INOSITOL; INSULIN; INSULIN RESISTANCE; LOGISTIC MODELS; MULTIVARIATE ANALYSIS; POLYCYSTIC OVARY SYNDROME; TESTOSTERONE; WAIST-HIP RATIO;

EID: 33646350288     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/diacare.29.02.06.dc05-1070     Document Type: Article

References (30)

1. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19:41- 47, 2004
2. Zawadsky JK, Dunaif A: Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In Current Issues in Endocrinology and Metabolism: Polycystic Ovary Syndrome. Dunaif A, Givens JR, Haseltine FP, Merriam GR, Eds. Cambridge, U.K., Blackwell Scientific Publications, 1992, p. 377-384
3. Baillargeon JP, Iuorno MJ, Nestler JE: Insulin sensitizers for polycystic ovary syndrome. Clin Obstet Gynecol 46:325-340, 2003
4. Baillargeon JP, Iuorno MJ, Nestler JE: Comparison of metformin and thiazolidinediones in the management of polycystic ovary syndrome. Curr Opin Endocrinol Diabetes 9:303-311, 2002
5. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, Zapanti ED, Bartzis MI: A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. JCEM 84:4006-4011, 1999
6. Cattrall FR, Healy DL: Long-term metabolic, cardiovascular and neoplastic risks with polycystic ovary syndrome. Best Pract Res Clin Obstet Gynecol 18:803-812, 2004
7. Nestler JE: Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications. Semin Reprod Endocrinol 15:111-122, 1997
8. De Leo V, la Marca A, Petraglia F: Insulinlowering agents in the management of polycystic ovary syndrome. Endocr Rev 24:633-667, 2003
9. Dunaif A, Segal KR, Futterweit W, Dobrjansky A: Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38:1165-1174, 1989
10. Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G: Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 340:1314-1320, 1999
11. Iuorno MJ, Jakubowicz DJ, Baillargeon JP, Dillon P, Gunn RD, Allan G, Nestler JE: Effects of D-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr Pract 8:417-423, 2002
12. Gerli S, Mignosa M, Di Renzo GC: Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial. Eur Rev Med Pharmacol Sci 7:151-159, 2003
13. Romero G, Larner J: Insulin mediators and the mechanism of insulin action. Adv Pharmacol 24:21-50, 1993
14. Saltiel AR: Second messengers of insulin action. Diabetes Care 13:244-256, 1990
15. Asplin I, Galasko G, Larner J: Chiro-inositol deficiency and insulin resistance: a comparison of the chiro-inositol- and the myo-inositol-containing insulin mediators isolated from urine, hemodialysate, and muscle of control and type II diabetic subjects. Proc Natl Acad Sci U S A 90:5924-5928, 1993
16. Kennington AS, Hill CR, Craig J, Bogardus C, Raz I, Ortmeyer HK, Hansen BC, Romero G, Larner J: Low urinary chiroinositol excretion in non-insulin-dependent diabetes mellitus. N Engl J Med 323:373-378, 1990
17. Baillargeon JP, Iuorno MJ, Jakubowicz DJ, Apridonidze T, He N, Nestler JE: Metformin therapy increases insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome. JCEM 89:242-249, 2004
18. Bergman RN, Phillips LS, Cobelli C: Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest 68:1456-1467, 1981
19. Yang YJ, Youn JH, Bergman RN: Modified protocols improve insulin sensitivity estimation using the minimal model. Am J Physiol 253:E595-E602, 1987
20. Bergman RN: Lilly lecture 1989: Toward physiological understanding of glucose tolerance: minimal-model approach. Diabetes 38:1512-1527, 1989
21. Pacini G, Bergman RN: MINMOD: a computer program to calculate insulin sensitivity and pancreatic responsivity from the frequently sampled intravenous glucose tolerance test. Comput Methods Programs Biomed 23:113-122, 1986
22. Nestler JE, Barlascini CO, Matt DW, Steingold KA, Plymate SR, Clore JN, Blackard WG: Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. JCEM 68:1027-1032, 1989
23. Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, Clore JN, Blackard WG: A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. JCEM 72:83-89, 1991
24. Nestler JE, Beer NA, Jakubowicz DJ, Beer RM: Effects of a reduction in circulating insulin by metformin on serum dehydro-epiandrosterone sulfate in nondiabetic men. JCEM 78:549-554, 1994
25. Sodergard R, Backstrom T, Shanbhag V, Carstensen H: Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. J Steroid Biochem 16:801-810, 1982
26. Ostlund REJ, McGill JB, Herskowitz I, Kipnis DM, Santiago JV, Sherman WR: D-chiro-inositol metabolism in diabetes mellitus. Proc Natl Acad Sci U S A 90:9988-9992, 1993
27. Craig JW, Larner J, Asplin CM: Chiro-inositol deficiency and insulin resistance. In Molecular Biology of Diabetes II. Draznin B, LeRoith D, Eds. Totowa, NJ, Humana, 1998, p. 343-362
28. Suzuki S, Kawasaki H, Satoh Y, Ohtomo M, Hirai M, Hirai A, Hirai S, Onoda M, Matsumoto M, Hinokio Y: Urinary chiro-inositol excretion is an index marker of insulin sensitivity in Japanese type II diabetes. Diabetes Care 17:1465-1468, 1994
29. Larner J, Craig JW: Urinary myo-inositol-to-chiro-inositol ratios and insulin resistance. Diabetes Care 19:76 -78, 1996
30. Shashkin PN, Shashkina EF, Fernqvist-Forbes E, Zhou YP, Grill V, Katz A: Insulin mediators in man: effects of glucose ingestion and insulin resistance. Diabetologia 40:557-563, 1997